Compare AVXL & BBCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVXL | BBCP |
|---|---|---|
| Founded | 2004 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Engineering & Construction |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 397.6M | 333.0M |
| IPO Year | N/A | 2017 |
| Metric | AVXL | BBCP |
|---|---|---|
| Price | $3.64 | $7.06 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $22.00 | $7.50 |
| AVG Volume (30 Days) | ★ 2.6M | 90.8K |
| Earning Date | 02-11-2026 | 01-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.16 |
| Revenue | N/A | ★ $395,562,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1.28 |
| P/E Ratio | ★ N/A | $42.73 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.86 | $4.78 |
| 52 Week High | $14.44 | $9.68 |
| Indicator | AVXL | BBCP |
|---|---|---|
| Relative Strength Index (RSI) | 33.60 | 62.79 |
| Support Level | $3.56 | $6.85 |
| Resistance Level | $4.88 | $7.16 |
| Average True Range (ATR) | 0.31 | 0.24 |
| MACD | 0.08 | 0.02 |
| Stochastic Oscillator | 6.06 | 85.39 |
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.
Concrete Pumping Holdings Inc is a provider of concrete pumping services and concrete waste management services in the fragmented United States and United Kingdom markets. Its large fleet of specialized pumping equipment and trained operators position it to deliver concrete placement solutions. The company's operating segment includes U.S. Concrete Pumping; U.K. Operations; U.S. Concrete Waste Management Services and Corporate. It generates maximum revenue from the U.S. Concrete Pumping segment. Geographically, it generates majority of the revenue from its business in United States.